Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: BBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) is a biotechnology company developing orthobiologic products for spine fusion markets, centered on bone regeneration using NELL-1-based technology. Although no specific SEC filings are listed here in the provided data, this page on Stock Titan is intended to organize the company’s regulatory documents and make them easier to review and interpret.
For a company like Bone Biologics, SEC filings typically include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe its clinical-stage development activities, orthobiologic product candidates such as NB1, and risk factors related to spine fusion markets and bone regeneration technology. Current reports on Form 8-K may discuss material events such as public offerings of common stock and warrants, reverse stock splits, or changes related to Nasdaq listing compliance, all of which Bone Biologics has addressed in its public news releases.
Stock Titan’s filings page is designed to surface these documents as they are made available through the EDGAR system and to pair them with AI-powered summaries. AI-generated overviews can help explain complex sections of filings, such as clinical development disclosures, intellectual property descriptions around rhNELL-1, and details of financing transactions. Users can also review information related to capital structure changes, including reverse stock split actions and registered offerings, which Bone Biologics has described in its press releases.
In addition, when Forms 3, 4, and 5 are filed, this page can be used to monitor insider share transactions and ownership updates. By combining real-time access to SEC documents with AI explanations, the Bone Biologics filings page aims to make the company’s regulatory history and disclosures more accessible to investors and other interested readers.
Bone Biologics Corp reported an insider equity award for its Chief Financial Officer, Deina Walsh, on a Form 4. On January 8, 2026, she received an employee stock option covering 8,335 shares of common stock with an exercise price of $1.55 per share. According to the filing, this option was granted under the company’s 2015 Equity Incentive Plan and vests and becomes exercisable immediately, with an expiration date of January 8, 2036.
The filing also shows she holds another employee stock option for 4,510 shares at an exercise price of $5.82, which is fully vested and expires on January 15, 2027, as well as 313 shares of common stock held directly after the reported transactions.
Bone Biologics Corp reported an insider equity award for its Chief Executive Officer, Jeff Frelick. On January 8, 2026, he received an employee stock option grant covering 16,668 shares of common stock with an exercise price of $1.55 per share. The filing states that this option was granted under the company’s 2015 Equity Incentive Plan, is exempt under Rule 16b-3, and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.
After this grant, Frelick directly holds 16,668 of these new options, along with previously held, fully vested options on 9,019 shares at an exercise price of $5.82 and options on 8 shares at an exercise price of $73,800. He also directly owns 360 shares of Bone Biologics common stock.
Bone Biologics Corporation filed a current report to furnish, rather than file, a press release dated January 8, 2026. The press release summarizes the company’s corporate, scientific and operational milestones achieved during 2025 and outlines its strategic outlook for 2026. This information is provided under Item 7.01 of the Exchange Act and is expressly not deemed filed or subject to Section 18 liabilities, nor incorporated by reference into other Securities Act or Exchange Act filings. The press release is included as Exhibit 99.1 to the report.
Bone Biologics Corporation (BBLG) filed its Q3 2025 report, highlighting continued clinical-stage investment with no revenue and a narrower quarterly net loss. Net loss was
The company completed a June 2025 public offering, issuing 793,750 shares and pre-funded warrants to purchase 456,250 shares, for net proceeds of
FAQ
What is the current stock price of Bone Biologics (BBLG)?
What is the market cap of Bone Biologics (BBLG)?
